Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) (CAS: 2148325-59-9)
Tamrintamab is an antibody-drug conjugate (ADC) that targets dipeptidase 3 (DPEP3 or MBD3), a glycosyl phosphatidylinositol-anchored metallopeptidase overexpressed in ovarian tumors. By binding specifically to DPEP3-expressing cells, Tamrintamab induces cytotoxicity, making it useful in targeted ovarian cancer research.
Key Features and Applications:
- DPEP3 Targeting: Binds selectively to DPEP3, which is highly expressed in ovarian cancer cells.
- Mechanism of Action: Once bound, it induces cytotoxic effects on DPEP3-positive tumor cells.
- Ovarian Cancer Research: Effective for studies on platinum-resistant or refractory ovarian cancer.
Handling and Administration:
- Formulation: Administered intravenously.
- Dosage: Tailored based on research protocols.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
